Barclays analyst Luke Sergott lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $70 and keeps an Overweight rating on the shares post the earnings report. The company offered a “straight forward” guidance with appropriately embedded conservatism, the analyst tells investors in a research note. The firm sees “plenty of sources of upside” as the year progresses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Reports Strong Revenue Growth in 2024
- Closing Bell Movers: Carvana down 8% on earnings, Palantir extends decline
- Exact Sciences reports Q4 EPS ($4.67), consensus (19c)
- Exact Sciences says plans to launch three new cancer tests in 2025
- Exact Sciences sees FY25 revenue $3.025B-$3.085B, consensus $3.06B